Denmark has briefly halted the use of the Oxford-AstraZeneca vaccine as each precaution, after news of a little number of lifeblood clots and one death.
The Danish health authority said it had been too early to mention whether there was a link to the AstraZeneca vaccine.
Austria earlier finished employing a batch like the drug, prompting the EU medicines office to mention there was not indication the vaccine caused blood clots.
The company says its safety has been studied extensively in clinical trials.
"Patient Safety is that the most important priority as AstraZeneca," a spokesperson said.
"Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine, which includes Covid-19 Vaccine AstraZeneca."
Peer-reviewed data confirmed it had been "generally well tolerated", the statement added.
The Danish decision came days next Austria suspended that use of a specific batch of the medicine because a lady died 10 times after taking it. Estonia, Latvia, Lithuania, and Luxemburg must also stopped using the batch.
Danish authorities said they were pausing the use of the vaccine for 14 days in what Health Minister Magnus Heunicke called a "precautionary measure".
Although no link had been established, he said "we must respond in a timely and careful manner" until a conclusion was reached.
The decision to place the vaccine on hold in Denmark and Austria may be a setback for an EU vaccination campaign that has stuttered into life, partly thanks to delays in delivery of the AstraZeneca drug.
The Danish authority said it had been not a simple decision because it was during most vital |the largest"> the most important and most important rollout within the country's history.
The EU medicines agency EMA said its safety committee was reviewing the Austrian case, but made clear that "there is currently no indication that vaccination has caused these conditions, which aren't listed as side effects with this vaccine".
The number of "thromboembolic events in vaccinated people is not any above that seen within the general population", it added.
How significant concern about the Oxford-AstraZeneca drug?
Officials say they need received reports of fatal or life-threatening blood clots during a small number of individuals who had recently received a dose of the Oxford-AstraZeneca vaccine. which will sound worrying, but it's not yet known if there's any connection between the 2 things.
It was on Sunday that one 49-year-old gentlewoman in Austria died from multiple family clots. She had been vaccinated 10 days earlier. Another one that received an attempt from an equivalent vaccine batch was also hospitalized for a grume within the lung.
As of 9 March 2021, two other reports of thromboembolism do received for this batch, ABV5300. It contained 1,000,000 doses and was delivered to 17 EU countries, including Austria and Denmark.
A full investigation into batch quality is ongoing, but a defect is taken into account unlikely.
Overall, 22 cases of thromboembolic events are reported among the three million people vaccinated with the AstraZeneca vaccine within the European Economic Area.
Any approved treatment, including vaccines, carries a risk of some side effects for a few people, but most are usually mild and severe ones are rare.
MORE| New Jersey mom dies of COVID days after giving birth to 3 son
0 Comments